DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the VIASKIN ® Peanut Patch increased their ...

Bezuclastinib demonstrates consistent biomarker and symptomatic improvement in patients with smoldering SM, a subgroup of NonAdvSM with high unmet need. As previously reported, bezuclastinib ...

Individual results vary. Dietary supplements are not substitutes for balanced nutrition, regular physical activity, or professional medical guidance. Consult a qualified healthcare provider before ...

Positioned as the "value king of high-capacity fast-charging power banks," the CUKTECH 25SE perfectly addresses Malaysia's growing need for efficient and reliable power solutions. Its core strength ...

Zhou Feng, Chief Strategy Officer of Fangzhou, commented, “The collaboration represents both complementary strengths and a step toward building a new healthcare ecosystem,” adding that the company ...

Informational 2026 customer report evaluates ReduBurn marketing claims, ingredient transparency, thermogenic resistance framing, pricing structure, published refund terms, and consumer due diligence ...

MADRID and CAMBRIDGE, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, ...

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the fourth quarter and full year 2025 ended December ...

In addition, Dr. Shaltiel will be speaking at the Advanced Therapies Congress in London in March 2026, Europe’s largest commercial cell and gene therapy conference and exhibition. The congress brings ...

These inducement grants were granted at an exercise price per share of $0.50 and $0.57, equal to the closing price of Femasys common stock on the date of employment as reported by Nasdaq. This grant ...

BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in five upcoming investor conferences in March.

Details for the Company’s participation are as follows: Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be accessed via the “ Events ” section of the Company’s ...